Key result
Adeno-associated virus (AAV) vectors continue to show promise in gene therapy, with recent commercial approvals and numerous successes across preclinical and clinical trials for various diseases.
Adeno-associated virus (AAV) continues to show promise as a viral vector for therapeutic gene delivery across a variety of diseases.
Answers are grounded in this paper and cite their sources.
May support AAV exploration in cardiovascular gene therapy; leaves open dedicated cardiac trials for safety and efficacy.
Adeno-associated virus (AAV) continues to be a promising viral vector for delivery of therapeutic genes in human gene therapy. In 2012, the European Commission approved Glybera (alipogene tiparvovec),1 an AAV vector carrying the human lipoprotein lipase gene for commercial use in treatment of lipoprotein lipase deficiency. In addition, within the past five years there have been numerous successes in preclinical, early, and late-stage clinical trials of AAV for treatment of a variety of diseases, including muscular dystrophy, hemophilia, Leber's congenital amaurosis retinopathy, age-related macular degeneration, cardiac disorders, cancer, and neurodegenerative disorders, such as Parkinson's disease and Canavan disease.
No takes yet. Share an insight, caveat, or question.
Summerford et al. (2016) conducted a review in Various genetic and acquired diseases. Adeno-associated virus (AAV) vectors was evaluated. Adeno-associated virus (AAV) vectors continue to show promise in gene therapy, with recent commercial approvals and numerous successes across preclinical and clinical trials for various diseases.
Synapse has enriched 10 related papers. Consider them for comparative context: